<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" content="KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today opened its expanded office in King of Prussia, Pennsylvania. Located on First Avenue, the new space is designed to accommodate the Company’s growing development, manufacturing, and commercial organizations.
” data-reactid=”5″ style=”margin: 0px 0px 1em; color: rgb(38, 40, 42); font-family: ‘Helvetica Neue’, Helvetica, Arial, sans-serif; font-size: 15px;” type=”text”> Paratek Pharmaceuticals, Inc., a biopharma company focused on developing therapies based on tetracycline chemistry, has expanded its office in King of Prussia, PA to accommodate its growing development, manufacturing, and commercial organizations.

“It’s an incredibly exciting time at Paratek as we get closer to potentially bringing our lead product candidate, omadacycline, to market,” said Evan Loh, M.D., president, chief operating officer, chief medical officer and director at Paratek. “Our expanded home in King of Prussia provides our growing team with the physical space and resources to fuel our continued commitment to bringing the very best in innovative antibiotic treatment options to patients to improve and potentially save lives.”

The renovated space will initially house approximately 30 full-time employees, most of which are focused on development and registration activities to support the company’s potential New Drug Application to FDA. Paratek plans to bring in additional resources to support the launch of omadacycline, a novel broad spectrum once-daily oral and intravenous antibiotic being developed to treat serious community-acquired infections such as acute skin and skin structure infections and community-acquired bacterial pneumonia. Paratek anticipates adding as many as 65 employees in King of Prussia over the next 24 months as registration and pre-commercial activities ramp up prior to launch.